CIBC Private Wealth Group LLC lowered its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 6.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 779,889 shares of the medical research company’s stock after selling 50,927 shares during the period. CIBC Private Wealth Group LLC owned about 0.37% of Edwards Lifesciences worth $119,456,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Capital Research Global Investors grew its position in shares of Edwards Lifesciences by 164.8% during the 3rd quarter. Capital Research Global Investors now owns 3,545,266 shares of the medical research company’s stock valued at $617,231,000 after acquiring an additional 2,206,539 shares during the period. FMR LLC grew its position in shares of Edwards Lifesciences by 32.9% during the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock valued at $977,456,000 after acquiring an additional 1,663,511 shares during the period. Janus Henderson Group PLC grew its position in shares of Edwards Lifesciences by 117.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,505,128 shares of the medical research company’s stock valued at $436,144,000 after acquiring an additional 1,350,879 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd grew its position in shares of Edwards Lifesciences by 211.7% during the 3rd quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 1,049,182 shares of the medical research company’s stock valued at $182,662,000 after acquiring an additional 712,537 shares during the period. Finally, Jennison Associates LLC grew its position in shares of Edwards Lifesciences by 70.8% during the 3rd quarter. Jennison Associates LLC now owns 1,444,384 shares of the medical research company’s stock valued at $251,467,000 after acquiring an additional 598,735 shares during the period. Institutional investors and hedge funds own 87.15% of the company’s stock.

Several equities research analysts recently issued reports on the company. Barclays assumed coverage on Edwards Lifesciences in a report on Monday, October 15th. They issued an “underweight” rating and a $143.00 price objective on the stock. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $180.00 to $190.00 in a report on Friday, January 18th. Deutsche Bank assumed coverage on Edwards Lifesciences in a report on Wednesday, January 2nd. They issued a “hold” rating and a $164.00 price objective on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price objective on shares of Edwards Lifesciences in a report on Sunday, February 3rd. Finally, Zacks Investment Research cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, October 25th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $169.86.

Shares of Edwards Lifesciences stock opened at $171.93 on Monday. The company has a market cap of $35.94 billion, a PE ratio of 36.58, a P/E/G ratio of 2.22 and a beta of 0.92. Edwards Lifesciences Corp has a 1-year low of $121.40 and a 1-year high of $175.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.92 and a current ratio of 2.61.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.17. The business had revenue of $977.70 million for the quarter, compared to analysts’ expectations of $973.72 million. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. During the same period in the previous year, the firm posted $0.94 EPS. As a group, analysts expect that Edwards Lifesciences Corp will post 5.22 earnings per share for the current fiscal year.

In other news, VP Catherine M. Szyman sold 700 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $155.00, for a total transaction of $108,500.00. Following the sale, the vice president now owns 24,482 shares of the company’s stock, valued at approximately $3,794,710. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 3rd. The shares were sold at an average price of $143.90, for a total transaction of $4,719,920.00. Following the sale, the chief executive officer now directly owns 75,926 shares in the company, valued at approximately $10,925,751.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 161,288 shares of company stock worth $24,202,388. Insiders own 1.84% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “CIBC Private Wealth Group LLC Sells 50,927 Shares of Edwards Lifesciences Corp (EW)” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/cibc-private-wealth-group-llc-sells-50927-shares-of-edwards-lifesciences-corp-ew/2812176.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Article: Analyst Ratings Trading

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.